Venlafaxine is an antidepressant drug that is being evaluated for the treatment of hot flashes in women who have breast cancer.
A study has found a link between the use of antidepressants and the development of gestational diabetes mellitus (GDM) in pregnant women.
A new study published in the current issue of Psychotherapy and Psychosomatics sheds new light on long-term studies with antidepressant drugs.
Researchers suspect that having Metabolic Syndrome makes it harder for older adults to respond to therapies for depression.
Chronic pain negatively impacts a person's quality of life. Often, over the counter pain medication, such as ibuprofen or aspirin, are ineffective in alleviating chronic pain. In these instances, a surprising choice is often a drug used to treat an entirely different condition - depression.
Older people receiving electroconvulsive therapy for their depression likely will need an additional treatment if insomnia is one of their symptoms, researchers report.
A new study in Personalized Medicine in Psychiatry explores how specific clinical and biological signals can help doctors select the most effective drug more quickly and with greater precision.
Although drug therapy is the accepted first-line treatment for panic disorders, 17% to 64% of patients do not respond adequately and continue to exhibit one of the most common symptoms of PD, the panic attack.
A new Université de Montréal study in the British Medical Journal reveals that antidepressants prescribed to pregnant women could increase the chance of having a baby with birth defects.
Seafood is the main component of European Christmas menus. But with rising concern about chemical pollution in the marine environment, is seafood safe to eat?
The majority of antidepressants prescribed to treat children and teenagers with major depression are ineffective and may even be unsafe, warn researchers.
An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.
Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.
More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.
Some three-quarters of North American women have menopausal hot flashes, but many cannot use hormones for medical reasons or choose not to. Numerous products and techniques are promoted for hot flashes, but do they work, and are they safe? To answer these questions, a North American Menopause Society panel of experts weighed the evidence and made recommendations in a position statement, "Nonhormonal management of menopause-associated vasomotor symptoms," published online today in the Society's journal, Menopause.
A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.
A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.
A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.
The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.
Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.